BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 28854594)

  • 1. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
    D'Hooghe T
    Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public welfare agenda or corporate research agenda?
    Singh A; Singh S
    Mens Sana Monogr; 2005 Mar; 3(1):41-80. PubMed ID: 22679348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commitments by the biopharmaceutical industry to clinical trial transparency: the evolving environment.
    Baronikova S; Purvis J; Southam E; Beeso J; Panayi A; Winchester C
    BMJ Evid Based Med; 2019 Oct; 24(5):177-184. PubMed ID: 30898790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Food for thought? Potential conflicts of interest in academic experts advising government and charities on dietary policies.
    Newton A; Lloyd-Williams F; Bromley H; Capewell S
    BMC Public Health; 2016 Aug; 16():735. PubMed ID: 27495802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The connection between academia and industry.
    Singh A; Singh S
    Mens Sana Monogr; 2005 Mar; 3(1):5-35. PubMed ID: 22679346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between authors of clinical practice guidelines and the pharmaceutical industry.
    Choudhry NK; Stelfox HT; Detsky AS
    JAMA; 2002 Feb; 287(5):612-7. PubMed ID: 11829700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scientific journals and their authors' financial interests: a pilot study.
    Krimsky S; Rothenberg LS; Stott P; Kyle G
    Psychother Psychosom; 1998; 67(4-5):194-201. PubMed ID: 9693346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials integrity: a CRO perspective.
    Beach JE
    Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethical pharmaceutical promotion and communications worldwide: codes and regulations.
    Francer J; Izquierdo JZ; Music T; Narsai K; Nikidis C; Simmonds H; Woods P
    Philos Ethics Humanit Med; 2014 Mar; 9():7. PubMed ID: 24679064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].
    Yamakawa K
    Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conflicts of interest in drug development: the practices of Merck & Co., Inc.
    Hirsch LJ
    Sci Eng Ethics; 2002 Jul; 8(3):429-42. PubMed ID: 12353373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Regulatory Assessment: Unpacking the Process Reveals Readiness to Pilot for Europe-An EFPIA View.
    Todd I; Faust R; Herrero-Martinez E; Hussain N; Kawinski A; Lennard A; Roux NL; Macdonald J; Mayer M; Palacios R; Dangy-Caye A
    Clin Ther; 2023 Nov; 45(11):1142-1147. PubMed ID: 37704457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Framework for industry engagement and quality principles for industry-provided medical education in Europe.
    Allen T; Donde N; Hofstädter-Thalmann E; Keijser S; Moy V; Murama JJ; Kellner T
    J Eur CME; 2017; 6(1):1348876. PubMed ID: 29644135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies.
    Modi ND; Kichenadasse G; Hoffmann TC; Haseloff M; Logan JM; Veroniki AA; Venchiarutti RL; Smit AK; Tuffaha H; Jayasekara H; Manning-Bennet A; Morton E; McKinnon RA; Rowland A; Sorich MJ; Hopkins AM
    BMC Med; 2023 Oct; 21(1):400. PubMed ID: 37872545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data sharing and the evolving role of statisticians.
    Manamley N; Mallett S; Sydes MR; Hollis S; Scrimgeour A; Burger HU; Urban HJ
    BMC Med Res Methodol; 2016 Jul; 16 Suppl 1(Suppl 1):75. PubMed ID: 27410483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Show us the money: lessons in transparency from state pharmaceutical marketing disclosure laws.
    Chimonas S; Rozario NM; Rothman DJ
    Health Serv Res; 2010 Feb; 45(1):98-114. PubMed ID: 19840133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.